user

Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.

被引：5
|
作者：
Le, Xiuning
Goldman, Jonathan Wade
Clarke, Jeffrey Melson
Tchekmedyian, Nishan
Piotrowska, Zofia
Chu, David
Bhat, Gajanan
Lebel, Francois M.
Socinski, Mark A.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA
[3] Duke Canc Inst, Durham, NC USA
[4] Pacific Shores Med Grp, Long Beach, CA USA
[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[6] North Shore Hematol Oncol Associates, East Setauket, NY USA
[7] Spectrum Pharmaceut, Irvine, CA USA
[8] AdventHlth Canc Inst, Orlando, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9514
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study
    Le, Xiuning
    Goldman, Jonathan
    Clarke, Jeffrey
    Techekmedyian, Nishan
    Piotrowska, Zofia
    Chu, David
    Bhat, Gajanan
    Lebel, Francois
    Socinski, Mark
    CANCER RESEARCH, 2020, 80 (16)
  • [2] Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients
    Cornelissen, R.
    Garassino, M. C.
    Le, X.
    Clarke, J.
    Tchekmedyian, N.
    Goldman, J.
    Lebel, F.
    Bhat, G.
    Socinski, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S173 - S174
  • [3] The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC
    Elamin, Y.
    Robichaux, J.
    Lam, V.
    Tsao, A.
    Lu, C.
    Blumenschein, G.
    Kurie, J.
    Brahmer, J.
    Li, S.
    Chen, T.
    Estrada-Bernal, A.
    Truini, A.
    Nilsson, M.
    Le, A.
    Tan, Z.
    Zhang, S.
    Doebele, R.
    Politi, K.
    Yang, Z.
    Liu, S.
    Wong, K.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1776 - S1776
  • [4] Molecular characteristics of EGFR exon20 mutations in NSCLC patients.
    Ji, Yinghua
    Wang, Jin
    Meng, Xiangli
    Xie, Jinling
    Lu, Ping
    Li, Mengmeng
    Luo, Ningning
    Qi, Yingxue
    Zhu, Xiaofeng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
    Prelaj, A.
    Bottiglieri, A.
    Galli, E.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R. M.
    de Braud, F.
    Torri, V.
    Garassino, M. C. C.
    Proto, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S976 - S977
  • [6] CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.
    Le, Xiuning
    Garassino, Marina Chiara
    Cornelissen, Robin
    Socinski, Mark A.
    Tchekmedyian, Nishan
    Molina, Julian R.
    Baik, Christina S.
    Leu, Sharon
    Dreiling, Lyndah
    Lebel, Francois M.
    Clarke, Jeffrey Melson
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [7] Preliminary Results of a Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
    Elamin, Y.
    Robichaux, J.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (08) : S1536 - S1536
  • [8] Activity of AUY922 in NSCLC Patients with EGFR Exon 20 Insertions
    Piotrowska, Zofi A.
    Smit, Egbert
    Costa, Daniel B.
    Huberman, Mark S.
    Oxnard, Geoffrey R.
    Gainor, Justin F.
    Heist, Rebecca
    Muzikansky, Alona
    Azzoli, Christopher G.
    Shaw, Alice
    Lin, Chia-Chi
    Liao, Wei-Yu
    Ho, Chao-Chi
    Niederst, Matthew J.
    Fulton, Linnea
    Engelman, Jeffrey A.
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S373 - S374
  • [9] Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib
    Yang, Juyin
    Yang, Jian
    Ban, Shao
    Li, Xinmin
    Chen, Xingde
    Yang, Jihua
    Qian, Jun
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : E198 - E200
12345